ESMO Asia 2025 | Real-world outcomes with S-1 in advanced cutaneous squamous cell carcinoma
Yasuhiro Nakamura, MD, PhD, Saitama Medical University International Medical Center, Saitama, Japan, comments on a multicenter retrospective analysis evaluating the efficacy and safety of S-1 in locally advanced and recurrent or metastatic cutaneous squamous cell carcinoma (cSCC). Real-world outcomes with S-1 showed response rates and survival broadly comparable to those reported with immune checkpoint inhibitors, with particularly favorable tolerability. Severe adverse events were infrequent, and no treatment-related deaths were observed. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Thank you very much. First, I’m very, very honored to be interested in our post at first. And S1 is a chemotherapeutic oral agent, which mainly constitutes a fluoropyrimidine, which is very easy to access in the Japanese population. Usually, it is used for head and neck cancer. And we explored this agent in locally advanced metastatic patients with cutaneous squamous cell carcinoma, which is very promising data, particularly in the locally advanced ones...
Thank you very much. First, I’m very, very honored to be interested in our post at first. And S1 is a chemotherapeutic oral agent, which mainly constitutes a fluoropyrimidine, which is very easy to access in the Japanese population. Usually, it is used for head and neck cancer. And we explored this agent in locally advanced metastatic patients with cutaneous squamous cell carcinoma, which is very promising data, particularly in the locally advanced ones. There is a good response rate, over 50%, and it’s a prolonged progression-free and overall survival, which is almost similar data. When we compared the phase 2 clinical trials of anti-PD-1, for example, cemiplimab and pembrolizumab. Our next goal is, fortunately, our country has access to anti-PD-1 treatment for cutaneous SCC, for example, nivolumab. And we at first retrospectively compared the S1 treatment and nivolumab treatment and confirmed the difference of clinical efficacy and survival.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
